BSH 2022 | European Society of Cardiology: 2022 cardio-oncology guidelines
Undergoing treatment for hematological malignancies can put patients at increased risk for developing cardiovascular complications. In this video, Alexander Lyon, MD, PhD, Imperial College London, London, UK, gives an overview of the European Society of Cardiology’s (ESC) cardio-oncology guidelines that will be released this year. These guidelines have been formulated by a group of cardiologists, oncologists, and hematologists, and will play an important role in the risk assessment, management, and long-term treatment of cardiovascular complications related to the treatment of various hematological malignancies. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Transcript (edited for clarity)
So over the last two years, the European Society of Cardiology has set up a task force, which is going to create the first ever ESC cardio-oncology guideline. And this will be published in August 2022. And there are oncologists, hematologists, as well as cardiologists involved in evaluating the evidence and bringing forward the appropriate management pathway.
So it’s very much a clinical guideline...
So over the last two years, the European Society of Cardiology has set up a task force, which is going to create the first ever ESC cardio-oncology guideline. And this will be published in August 2022. And there are oncologists, hematologists, as well as cardiologists involved in evaluating the evidence and bringing forward the appropriate management pathway.
So it’s very much a clinical guideline. Who needs risk assessment, what to do with the high-risk, the medium-risk, or the low-risk patient, what to do if one of your patients presents with a cardiovascular complication whilst they’re on their treatment.
And then for survivors, so many patients have completed their treatments for lymphoma, leukemia, who needs long-term follow up? What are the risks in the medium and long-term, which we understand from treatments like anthracycline chemotherapy and high dose radiation therapy to the chest.
And of course, some patients are just left on long-term treatment for their CML or their CLL, and therefore thinking about how to address the cardiovascular diseases that develop over time. So hopefully that will be a useful educational resource and I’d encourage you all to look out for it when it’s published in the European Heart Journal in August this year.
Read more...
